Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genvoya for HIV Post-exposure Prophylaxis
NCT02998320Phase 3Completed
- Sponsor
- GERES
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by GERES. Primary endpoint: Proportion of patients taking the uninterrupted HIV post-exposure prophylaxis at 28 days. Started Mar 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02998320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998320.